STAXYN Drug Patent Profile
✉ Email this page to a colleague
When do Staxyn patents expire, and what generic alternatives are available?
Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has fifty-three patent family members in thirty-eight countries.
The generic ingredient in STAXYN is vardenafil hydrochloride. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Staxyn
A generic version of STAXYN was approved as vardenafil hydrochloride by TEVA PHARMS on May 3rd, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for STAXYN?
- What are the global sales for STAXYN?
- What is Average Wholesale Price for STAXYN?
Summary for STAXYN
International Patents: | 53 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Patent Applications: | 4 |
Drug Prices: | Drug price information for STAXYN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for STAXYN |
What excipients (inactive ingredients) are in STAXYN? | STAXYN excipients list |
DailyMed Link: | STAXYN at DailyMed |
Paragraph IV (Patent) Challenges for STAXYN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
STAXYN | Orally Disintegrating Tablets | vardenafil hydrochloride | 10 mg | 200179 | 1 | 2011-12-22 |
US Patents and Regulatory Information for STAXYN
STAXYN is protected by one US patents.
Patents protecting STAXYN
Pharmaceutical forms with improved pharmacokinetic properties
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for STAXYN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for STAXYN
See the table below for patents covering STAXYN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Austria | E552828 | ⤷ Sign Up | |
Portugal | 1858490 | ⤷ Sign Up | |
Norway | 20002444 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |